leadf
logo-loader
viewArix Bioscience PLC

Arix Bioscience portfolio company LogicBio announces IND clearance for LB-001

LogicBio said it expects patient enrolment to begin in early 2021.

Arix Bioscience PLC -

Arix Bioscience PLC (LON:ARIX) has noted portfolio company LogicBio Therapeutics’ (Nasdaq:LOGC) approval for a Phase 1/2 clinical trial of its LB-001 programme for very young children with methylmalonic acidemia (MMA) .

LogicBio said it expects patient enrolment to begin in early 2021.

“We’re pleased to announce our plans for developing LB-001 in pediatric patients with MMA,” said Fred Chereau, CEO of LogicBio.

“This is an important milestone for patients, their families, our company and for the genetic medicines space more broadly as we believe this is the first Investigational New Drug application (IND) clearance for an in vivo gene editing program harnessing homologous recombination,”

Quick facts: Arix Bioscience PLC

Price: 151 GBX

LSE:ARIX
Market: LSE
Market Cap: £204.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE flounders as imminent Brexit talks loom

The FTSE is mixed this Tuesday despite the weaker pound. Sterling is still battling no deal Brexit fears as the UK Prime Minister Boris Johnson threatens that if no progress on the talks with the EU is made week, preparations for a no deal will be ramped up. Britain’s biggest sports retailer...

on 8/9/20

2 min read